About Q4 results, excluding one-off inventory adjustment in Sun Pharma's domestic business, Q4 results were better than I-direct estimates on all fronts led by robust growth in US and efficient cost control measures. Adjusted revenues of I-direct pharma universe grew 14.9% YoY to | 46359 crore. Overall US pie reported one of the best results in the recent past driven by 1) volume gains, 2) mitigating base business price erosion, 3) new launches and 4) certain one-time sales besides currency tailwinds. Indian formulations also reported decent growth despite soft season in acute...